ID   B9013HCB
AC   CVCL_B0CH
SY   Melanoma model 2; M2
DR   ATCC; CRL-3474
DR   GEO; GSM4301283
DR   Wikidata; Q108819897
RX   PubMed=32284588;
CC   Doubling time: ~24-36 hours (ATCC=CRL-3474).
CC   Transformant: NCIt; C17231; Ultraviolet radiation.
CC   Omics: Genomics; Whole exome sequencing.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Breed/subspecies: C57BL/6 BrafCA/+, Cdkn2aflox/+, Tyr-CreERT2-tg, Hgftg.
DI   NCIt; C21790; Mouse melanoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
SX   Female
AG   Adult
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 10-04-25; Version: 6
//
RX   PubMed=32284588; DOI=10.1038/s41591-020-0818-3; PMCID=PMC8482620;
RA   Perez-Guijarro E., Yang H.H., Araya R.E., El Meskini R., Michael H.T.,
RA   Vodnala S.K., Marie K.L., Smith C., Chin S., Lam K.C., Thorkelsson A.,
RA   Iacovelli A.J., Kulaga A., Fon A.-Y., Michalowski A.M., Hugo W.,
RA   Lo R.S., Restifo N.P., Sharan S.K., Van Dyke T., Goldszmid R.S.,
RA   Ohler Z.W., Lee M.P., Day C.-P., Merlino G.T.;
RT   "Multimodel preclinical platform predicts clinical response of
RT   melanoma to immunotherapy.";
RL   Nat. Med. 26:781-791(2020).
//